Moschos SJ - Search Results

1

Importance of glycolysis and oxidative phosphorylation in advanced melanoma.

Ho J, de Moura MB, Lin Y, Vincent G, Thorne S, Duncan LM, Hui-Min L, Kirkwood JM, Becker D, Van Houten B, Moschos SJ. Ho J, et al. Among authors: moschos sj. Mol Cancer. 2012 Oct 9;11:76. doi: 10.1186/1476-4598-11-76. Mol Cancer. 2012. PMID: 23043612 Free PMC article.

2

Development of [¹⁸F]F-5-OMe-Tryptophans through Photoredox Radiofluorination: A New Method to Access Tryptophan-Based PET Agents.

Wu X, Ma X, Zhong Y, Chen W, Xu M, Zhang H, Wang L, Tu X, Han Z, Zhao W, Wu Z, Moschos SJ, Li Z. Wu X, et al. Among authors: moschos sj. J Med Chem. 2023 Mar 9;66(5):3262-3272. doi: 10.1021/acs.jmedchem.2c01544. Epub 2023 Feb 24. J Med Chem. 2023. PMID: 36826835 Free PMC article.

3

Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.

Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Moschos SJ, et al. J Clin Oncol. 2004 Jan 1;22(1):11-4. doi: 10.1200/JCO.2004.10.952. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665613 No abstract available.

4

Melanoma.

Moschos SJ, Konstantinopoulos PA, Kirkwood JM. Moschos SJ, et al. Cancer Chemother Biol Response Modif. 2005;22:563-90. Cancer Chemother Biol Response Modif. 2005. PMID: 16110629 Review. No abstract available.

5

Interferons in the treatment of solid tumors.

Moschos S, Varanasi S, Kirkwood JM. Moschos S, et al. Cancer Treat Res. 2005;126:207-41. doi: 10.1007/0-387-24361-5_9. Cancer Treat Res. 2005. PMID: 16209068 Review. No abstract available.

6

Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.

Kirkwood JM, Moschos S, Wang W. Kirkwood JM, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2331s-2336s. doi: 10.1158/1078-0432.CCR-05-2538. Clin Cancer Res. 2006. PMID: 16609054 Review.

7

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Moschos SJ, et al. J Clin Oncol. 2006 Jul 1;24(19):3164-71. doi: 10.1200/JCO.2005.05.2498. J Clin Oncol. 2006. PMID: 16809739 Clinical Trial.

8

SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas.

Moschos SJ, Smith AP, Mandic M, Athanassiou C, Watson-Hurst K, Jukic DM, Edington HD, Kirkwood JM, Becker D. Moschos SJ, et al. Oncogene. 2007 Jun 21;26(29):4216-25. doi: 10.1038/sj.onc.1210216. Epub 2007 Feb 12. Oncogene. 2007. PMID: 17297476

9

Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.

Moschos SJ, Odoux C, Land SR, Agarwala S, Friedland D, Volker KM, Sidor C, Wong M, Kirkwood JM. Moschos SJ, et al. Melanoma Res. 2007 Jun;17(3):193-200. doi: 10.1097/CMR.0b013e3281ad91a3. Melanoma Res. 2007. PMID: 17505265 Clinical Trial.

10

Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma.

Moschos S, Kirkwood JM. Moschos S, et al. Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):451-8. doi: 10.1016/j.cytogfr.2007.06.020. Epub 2007 Aug 10. Cytokine Growth Factor Rev. 2007. PMID: 17693125 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters